00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
22:34 , May 14, 2019 |  BC Extra  |  Clinical News

May 14 Clinical Quick Takes: Myovant, Solid, Minerva, Modus, Zealand

Myovant tumbles after Phase III uterine fibroid data  Myovant Sciences Ltd. (NYSE:MYOV) lost $4.39 (25%) to $12.83 Tuesday despite reporting that relugolix (TAK-385) met the primary endpoint of a better response rate than placebo in...
19:15 , May 10, 2019 |  BioCentury  |  Emerging Company Profile

HopeMed: Targeting PRLR for chronic diseases

HopeMed spun out of Peking University last month with a mAb against the prolactin receptor from Bayer that could provide a safe alternative to competing therapies for endometriosis and alopecia. Hope Medicine Inc. has exclusive...
19:49 , Feb 15, 2019 |  BC Week In Review  |  Clinical News

Xtandi reduces radiographic PFS by 61% in metastatic hormone-sensitive prostate cancer

Astellas Pharma Inc. (Tokyo:4503) and Pfizer Inc. (NYSE:PFE) reported that Xtandi enzalutamide plus androgen deprivation therapy (ADT) reduced the risk of radiographic progression or death, the primary endpoint, by 61% vs. ADT alone in the...
21:03 , Jan 30, 2019 |  BC Innovations  |  Translation in Brief

Epigenetic links in endometriosis

An HDAC3-mediated epigenetic pathway could lead to new therapies and markers for endometriosis and associated infertility. Researchers from Michigan State University and Yonsei University College of Medicine have linked an epigenetic pathway involving HDAC3 to...
03:14 , Dec 8, 2018 |  BioCentury  |  Regulation

Path to opioid-free pain relief

To jump-start development of analgesics that can help stem the opioid crisis, companies want FDA’s upcoming guidelines to reduce uncertainty around outcomes that constitute clinically meaningful opioid sparing. But while an advisory panel put some...
15:27 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

FDA approves AbbVie's Orilissa for endometriosis pain

FDA approved Orilissa elagolix from AbbVie Inc. (NYSE:ABBV) for the management of moderate to severe pain associated with endometriosis. AbbVie expects to launch the drug early next month at a wholesale acquisition cost (WAC) of...
20:44 , Jun 22, 2018 |  BC Week In Review  |  Clinical News

ObsEva's linzagolix meets in Phase IIb for endometriosis-associated pain

ObsEva S.A. (NASDAQ:OBSV) said three of four doses of linzagolix (OBE2109, KLH-2109) met the primary endpoint in the Phase IIb EDELWEISS trial to treat moderate to severe endometriosis-associated pain. The company plans to present additional...
19:03 , Jun 22, 2018 |  BC Week In Review  |  Financial News

ObsEva raises $73M follow-on

Reproductive health company ObsEva S.A. (NASDAQ:OBSV) raised $73.1 million through the sale of 4.8 million shares at $15.39 in a follow-on underwritten by J.P. Morgan, Credit Suisse Securities (USA), Jefferies, Wedbush Securities and H.C. Wainwright....
20:13 , Jun 20, 2018 |  BC Extra  |  Financial News

ObsEva raises $73M on heels of linzagolix data

ObsEva S.A. (NASDAQ:OBSV) raised $73.1 million through the sale of 4.8 million shares at $15.39 in a follow-on underwritten by J.P. Morgan, Credit Suisse Securities (USA), Jefferies, Wedbush Securities and H.C. Wainwright. The price is...